Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | WDR91 | A4D1P6 | 2/20 | 0.50 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2183374 | 0.90 | NOTUM (0.75) | KMT2AMEN1NOTUMALDH1A1NPSR1 | |
| SCHEMBL16695124 | 0.90 | NOTUM (0.75) | KMT2AMEN1NOTUMALDH1A1NPSR1 | |
| Hydrochloric Acid SCHEMBL30098430 | 0.89 | NOTUM (0.73) | KMT2AMEN1NOTUMALDH1A1NPSR1 | |
| SCHEMBL613112 | 0.87 | NOTUM (0.81) | KMT2AMEN1NOTUMALDH1A1HSD17B10 | |
| SCHEMBL4961935 | 0.87 | NOTUM (0.81) | KMT2AMEN1NOTUMALDH1A1HSD17B10 | |
| SCHEMBL79756 | 0.86 | WDR91 (0.52) | KMT2AMEN1NOTUMLMNALRRK2 | |
| SCHEMBL2448228 | 0.84 | WDR91 (0.51) | KMT2AMEN1NOTUMLMNAWDR91 | |
| SCHEMBL2449550 | 0.84 | NOTUM (0.61) | KMT2AMEN1NOTUMWDR91PBK | |
| SCHEMBL2451481 | 0.84 | WDR91 (0.66) | KMT2AMEN1NOTUMWDR91PBK | |
| SCHEMBL2449229 | 0.84 | NOTUM (0.64) | KMT2AMEN1NOTUMLMNAWDR91 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758580-A4 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-16 | — | — | EP | claimed |
| EP-1758580-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2006012226-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-12419888-B2 | Methods of treating elevated plasma cholesterol | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2025-09-23 | — | — | US | disclosed |
| US-20220296593-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2022-09-22 | — | — | US | disclosed |
| CN-114746151-A | Aryl heterocyclic compounds as Kv1.3 potassium Shaker channel blockers | D·E·萧尔研究有限责任公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-2362775-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| CN-1297559-C | Fused bicyclic pyrimidine derivatives | KYORIN SEIYAKU KK (JP) | 2007-01-31 | — | — | CN | disclosed |
| CN-1620459-A | Fused bicyclic pyrimidine derivatives | KYORIN SEIYAKU KK (JP) | 2005-05-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296593-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | PCSK9, LDLR, CETP | KMT2A 3355/4885MEN1 1446/4885NOTUM 507/4885 |
| US-12419888-B2 | Methods of treating elevated plasma cholesterol | PCSK9, LDLR, CETP | KMT2A 3307/4885MEN1 1583/4885NOTUM 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.